

Supplemental Table 1. Endoscopy-related characteristics by cancer type, N=39

	Total	Melanoma	GU	GI	Lung Head/Neck	Hematolo gical	Renal
At the time of colitis diagnosis	No. (%)	14 (35.8)	10 (25.6)	7 (17.9)	6 (15.3)	1 (2.5)	1 (2.4)
Endoscopic findings							
Inflammation							
Ulcers	2 (5.1)	1 (7.1)	1 (10)	0 (0)	0 (0)	0 (0)	0 (0)
Non-ulcer inflammation	30 (76.9)	12 (85.7)	6 (60)	4 (57.1)	6 (100)	1 (100)	1 (100)
Normal	7 (17.9)	1 (7.1)	3 (30)	3 (42.8)	0 (0)	0 (0)	0 (0)
Other							
Polyps	3 (7.6)	2 (14.2)	1 (10)	0 (0)	0 (0)	0 (0)	0 (0)
Histologic findings							
Acute inflammation	18 (46.1)	6 (42.8)	4 (40)	2 (28.5)	4 (66.6)	0 (0)	0 (0)
Chronic inflammation	10 (25.6)	4 (28.4)	2 (20)	3 (42.8)	1 (16.6)	0 (0)	0 (0)
Microscopic colitis	3 (7.6)	2 (14.2)	0 (0)	0 (0)	1 (16.6)	0 (0)	0 (0)
Normal	8 (20.5)	2 (14.2)	4 (40)	2 (28.5)	0 (0)	0 (0)	0 (0)
Treatment of IMC							
Corticosteroids only	16 (41.0)	7 (50.0)	2 (20)	4 (57.1)	2 (33.3)	1 (100)	0 (0)
Corticosteroids plus infiximab only	8 (20.5)	1 (7.1)	5 (50)	0 (0)	2 (33.3)	0 (0)	0 (0)
Corticosteroids plus vedolizumab only	7 (17.9)	0 (0)	1 (10)	3 (42.8)	2 (33.3)	0 (0)	1 (100)
Multiple treatment lines	8 (20.5)	6 (42.8)	2 (20)	0 (0)	0 (0)	0 (0)	0 (0)
At the time of follow-up endoscopy							
Endoscopic findings							
Inflammation							

Erythema, erosions, vascular congestion and inflammation	16 (41)	8 (57.1)	4 (40)	2 (28.5)	2 (33.3)	0 (0)	0 (0)
Normal	23 (58.9)	6 (42.8)	6 (60)	5 (71.4)	4 (66.6)	1 (100)	1 (100)
Other							
New polyps	20 (51.2)	7 (50)	5 (50)	4 (57.1)	3 (50)	0 (0)	1 (100)
Stricture	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Perforation	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Histologic findings							
Inflammatory findings							
Inflammation	19 (48.7)	8 (57.1)	4 (40)	3 (42.8)	4 (66.6)	0 (0)	0 (0)
Normal histologic findings	20 (51.2)	6 (42.8)	6 (60)	4 (57.1)	2 (33.3)	1 (100)	1 (100)
Other							
Adenoma polyps	13 (33.3)	6 (42.8)	3 (30)	2 (28.5)	1 (16.6)	0 (0)	1 (100)

Abbreviations: CTCAE v5, Common Terminology Criteria for Adverse Events version 5; ICI, immune checkpoint inhibitor; IMC, immune-mediated colitis; IQR, interquartile range; TNF, tumor necrosis factor; FMT, fecal microbiota transplantation; GU, genitourinary; GI, gastrointestinal.

Supplemental Table 2. Characteristics of patients with and without adenoma, N=39

Characteristic	Adenoma polyps* No. (%) N=13	No adenoma polyps No. (%) N=26	<i>p</i>
Baseline characteristics			
Age, years, median (IQR)	66 (60-70)	62 (48-68)	0.268
Sex = male	11 (84.6)	21 (80.7)	1.000
Race = white	11 (84.6)	24 (92.2)	0.589
Cancer type			0.943
Melanoma	6 (46.1)	8 (30.7)	
Genitourinary	3 (23)	7 (26.9)	
Gastrointestinal	3 (23.1)	4 (15.3)	
Lung/head/neck	1 (7.6)	5 (19.2)	
Hematological	0 (0)	1 (3.8)	
Renal	0 (0)	1 (3.8)	
Type of ICI			0.180
Anti-CTLA-4 monotherapy	0 (0)	2 (7.6)	
Anti-PD-1/L1 monotherapy	0 (0)	5 (19.2)	
Combination anti-CTLA-4 and anti-PD-1/L1	13 (100)	19 (73)	
Previous colonoscopy screening before colitis	3 (23.1)	3 (11.5)	0.380
Duration of previous colonoscopy before colitis to colitis onset, months, median (IQR), n=6	7.0 (6.1-16.4)	9.7 (4.8-35.4)	1.000
Personal history of colon polyps before colitis, n=6	3 (100)	3 (100)	--
Characteristics of index colitis			
Polyps on initial endoscopic evaluation for colitis	2 (15.4)	1 (3.8)	0.253
Grades of preparation on initial endoscopy, n=30‡			1.000
Adequate, good, or excellent preparation	6 (60)	13 (60)	

Fair or poor preparation	4 (40)	7 (30)	
Endoscopic findings of initial colitis event			0.703
Ulcers	0 (0)	2 (7.6)	
Non-ulcer inflammation	10 (76.9)	20 (76.9)	
Normal	3 (23.1)	4 (15.3)	
Histologic findings of initial colitis event			0.637
Acute	5 (38.4)	13 (50)	
Chronic	3 (23.1)	7 (26.9)	
Normal	3 (23.1)	5 (19.2)	
Microscopic colitis	2 (15.3)	1 (3.8)	
Treatment of colitis			0.193
Corticosteroids alone	7 (53.8)	10 (38.4)	
Multiple treatment lines [†]	6 (46.1)	16 (53.8)	
At the time of follow-up endoscopy			
Grade of preparation on follow-up endoscopy			1.000
Adequate, good, or excellent preparation, n=30§	7 (70)	17 (85)	
Fair or poor preparation	3 (30)	3 (15)	
Active inflammation on follow-up endoscopy	3 (30)	13 (50)	0.176
Active inflammation on follow-up histology	10 (76.9)	9 (34.6)	0.380
Duration from colitis diagnosis to last follow-up endoscopy, months, median (IQR)	14.8 (8.9-30.5)	4.11 (2.4-15.2)	0.004*
Duration from colitis diagnosis to last follow-up in months, median (IQR)	13.6 (11.2-17.15)	15.5 (7.8-41.2)	0.780

Abbreviations: CTLA-4, cytotoxic T lymphocyte antigen 4; FMT, fecal microbiota transplant; ICI, immune checkpoint inhibitor; IQR, interquartile range; PD-1/PD-L1, programmed cell death 1/programmed death ligand 1.

7 patients (18%) were females.

3 patients (7.6%) were Hispanic and 1 patient (2.5%) African American.

*11 patients had tubular adenomas, 2 had tubulovillous adenomas. 1 patient had polyps <5 mm in size, and 11 had polyps >5 mm.

†Other add-on biologic treatment included the following; infliximab only: 2 (15.3%) patients in the adenoma group and 6 (23%) patients in the non-adenoma group, vedolizumab only: 3 (23%) patients in the adenoma group and 6 (23%) patients in the non-adenoma group, both infliximab and vedolizumab: 1 (7.6%) patients in the adenoma group and 3 (11.5%) patients in the non-adenoma group, ustekinumab add-on: 1 (3.8%) patient in the non-adenoma group. 4 patients in the non-adenoma group received FMT (1 FMT + corticosteroids, 2 FMT + vedolizumab, 1 FMT + ustekinumab).

‡30 patients had described the grade of bowel preparation on initial endoscopy, the remaining 9 patients were missing this feature.

§30 patients had described the grade of bowel preparation on follow-up endoscopy, the remaining 9 patients were missing this feature.